openPR Logo
Press release

Robust pipeline and subsequent launches in Irritable Bowel Syndrome Treatment Market

08-12-2020 02:42 PM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market

Global irritable bowel syndrome treatment market over the forecast period. Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for symptom specific irritable bowel syndrome. Allergan plc received the U.S. Food & Drug Administration (FDA) approval for Viberzi (eluxadoline) for the treatment of IBS in adult men and women in 2015. Also, the company received approval of Health Canada for IBS-D in 2017.

Valeant Pharmaceuticals International, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan for the treatment of IBS-D in 2015. The major players are also expanding the product portfolio and their IBS therapies through mergers and acquisitions. Valeant Pharmaceuticals International, Inc. acquired Salix Pharmaceuticals, Inc. in 2015 along with the latter’s popular brand Xifaxan. The manufacturers are spreading the awareness about IBS through direct-to-consumer campaign advertisements for IBS drugs. For instance, Allergan and Ironwood Pharmaceuticals launched the first DTC campaign for Viberzi in 2015.

Key players in the market are focused on developing novel gastrointestinal therapies for treatment of irritable bowel syndrome by actively investing in research and development of pipeline products. For instance, Synergy Pharmaceuticals, Inc. announced the acceptance of supplemental new drug application for Trulance (Plecanatide) for IBS treatment in 2017.

Furthermore, Sucampo Pharmaceuticals, Inc.’s pipeline products include lubiprostone for pediatric functional constipation (6 years – 17 years) in phase two and lubiprostone alternate formulation for pediatric constipation (6 months – 6 years). Also, Ardelyx, Inc. reported successful phase 3 T3MPO trial of Tenapanor in patients with irritable bowel syndrome with constipation. Astellas Pharma, Inc. is conducting clinical trials for ASP7147, in the treatment of IBS. Norgine B.V. is having Plenvu, as osmotic laxative in clinical trials and the company entered into an agreement with Noventure to commercialize Gelsectan in Spain, Portugal and Andorra in 2017. Synthetic Biologics, Inc. is developing SYN-010 (modified-release reformulation of lovastatin lactone) as a therapy in irritable bowel syndrome with constipation.

Request a sample report @ https://www.coherentmarketinsights.com/insight/request-sample/506

Some major players operating in the irritable bowel syndrome treatment market include Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Robust pipeline and subsequent launches in Irritable Bowel Syndrome Treatment Market here

News-ID: 2110772 • Views: 361

More Releases from Coherent Market Insights (CMI)

Computational Biology Market In-depth Study 2020 | Chemical Computing Group Inc. …
COVID-19 Outbreak-Global Computational Biology Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the COVID-19 Outbreak-Global Computational Biology Market. Some of the key players profiled in the study
Telerehabilitation Systems Market Revenue Opportunists by Key Vendors | 270 Visi …
COVID-19 Outbreak-Global Telerehabilitation Systems Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the COVID-19 Outbreak-Global Telerehabilitation Systems Market. Some of the key players profiled in the study
Personal Emergency Response Systems Market Revenue Develop Rapidly by Top Player …
COVID-19 Outbreak-Global Personal Emergency Response Systems Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the COVID-19 Outbreak-Global Personal Emergency Response Systems Market. Some of the key players
Wearable Patch Market In-depth Study 2020 | Hill-Rom Holdings, Inc. (Welch Allyn …
COVID-19 Outbreak-Global Wearable Patch Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by CMI evaluating the market, highlighting opportunities, analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the COVID-19 Outbreak-Global Wearable Patch Market. Some of the key players profiled in the study

All 5 Releases


More Releases for Pharma

Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Erythrocyte Catalase Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Erythrocyte Catalase Market" across the global, regional and country level. The report provides 360° analysis of "Erythrocyte Catalase Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Erythrocyte Catalase industry, and estimates the future trend of Erythrocyte Catalase market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business